Royal Bank Of Canada Reaffirms Sector Perform Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)

Key Points

• Royal Bank of Canada reaffirmed a "sector perform" rating on BioMarin with a $66 price target, implying about a 21% upside from the prior close.
• BioMarin raised its FY-2026 revenue guidance and posted a Q1 revenue beat, but Q1 EPS missed estimates ($0.76 vs. $0.94), creating mixed near-term catalysts for the stock.
• Analysts hold a consensus of "Moderate Buy" (consensus target $90.91)

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report)'s stock had its "sector perform" rating reaffirmed by research analysts at Royal Bank Of Canada in a research note issued on Tuesday,Benzinga reports. They currently have a $66.00 price objective on the biotechnology company's stock. Royal Bank Of Canada's price objective would suggest a potential upside of 20.99% from the stock's previous close.

Other equities research analysts have also issued reports about the company. Truist Financial upgraded BioMarin Pharmaceutical to a "strong-buy" rating in a research note on Wednesday, March 25th. Bank of America lowered their target price on BioMarin Pharmaceutical from $97.00 to $85.00 and set a "buy" rating for the company in a report on Wednesday, March 11th. Morgan Stanley assumed coverage on BioMarin Pharmaceutical in a report on Monday, April 27th. They set an "overweight" rating and a $120.00 target price for the company. Wells Fargo & Company raised their price objective on BioMarin Pharmaceutical from $70.00 to $75.00 and gave the company an "overweight" rating in a report on Wednesday, February 18th. Finally, Stifel Nicolaus set a $68.00 price objective on BioMarin Pharmaceutical in a report on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, BioMarin Pharmaceutical has a consensus rating of "Moderate Buy" and a consensus target price of $90.91.

BioMarin Pharmaceutical Stock Down 1.6%

Shares of BioMarin Pharmaceutical stock traded down $0.91 during midday trading on Tuesday, hitting $54.55. The company's stock had a trading volume of 991,271 shares, compared to its average volume of 1,999,276. BioMarin Pharmaceutical has a 1-year low of $50.76 and a 1-year high of $66.28. The stock has a 50-day simple moving average of $56.93 and a 200-day simple moving average of $56.32. The company has a quick ratio of 3.50, a current ratio of 5.21 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $10.54 billion, a P/E ratio of 30.58, a PEG ratio of 0.54 and a beta of 0.23.

Insider Buying and Selling

In other news, EVP Gregory R. Friberg sold 6,326 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $60.38, for a total value of $381,963.88. Following the completion of the sale, the executive vice president directly owned 37,578 shares in the company, valued at approximately $2,268,959.64. The trade was a 14.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Charles Greg Guyer sold 16,486 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $60.46, for a total transaction of $996,743.56. Following the completion of the transaction, the executive vice president directly owned 79,953 shares in the company, valued at $4,833,958.38. This trade represents a 17.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.85% of the stock is currently owned by insiders.

Institutional Trading of BioMarin Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the stock. Activest Wealth Management bought a new stake in shares of BioMarin Pharmaceutical during the fourth quarter worth $26,000. Quent Capital LLC bought a new stake in shares of BioMarin Pharmaceutical during the third quarter worth $28,000. CIBC Private Wealth Group LLC grew its stake in shares of BioMarin Pharmaceutical by 38.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company's stock worth $39,000 after buying an additional 179 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of BioMarin Pharmaceutical during the third quarter worth $40,000. Finally, Smartleaf Asset Management LLC grew its stake in shares of BioMarin Pharmaceutical by 92.5% during the third quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company's stock worth $40,000 after buying an additional 360 shares during the last quarter. Institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Company raised FY-2026 revenue guidance to $3.825–$3.925 billion (midpoint implies ~20% Y/Y growth) and cited recent additions (GALAFOLD®, POMBILITI® + OPFOLDA®) as drivers — a material top-line upgrade that supports longer-term growth expectations. Read More.
• Positive Sentiment: Q1 revenue beat consensus: $766.21M vs. ~$752M consensus, showing organic revenue growth despite the EPS miss. This revenue strength helps justify the raised guidance. Read More.
• Positive Sentiment: Broker consensus remains constructive overall — the stock carries an average “Moderate Buy” from analysts, which cushions downside risk from a single-quarter miss. Read More.
• Neutral Sentiment: Full Q1 2026 earnings call transcript and the investor presentation are available for details on product trends, margin drivers and pipeline commentary — useful for parsing management’s tone on sustainment of revenue growth. Read More. • Read More.
• Negative Sentiment: Q1 EPS missed Street estimates: $0.76 vs. $0.94 consensus (down from $0.95 a year ago), and reported EPS missed both Zacks and other consensus figures — an immediate catalyst for selling pressure. Read More. • Read More.
• Negative Sentiment: HC Wainwright reaffirmed a “neutral” rating with a $55 price target (~slight downside to recent levels), signaling limited near-term upside from the analyst community despite the revenue beat. Read More.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.